

Liquid Biopsy Market To See Record Break Revenue \$6.80 billion by 2030 at 20.9% CAGR

The global Liquid Biopsy Market garnered \$1.20 billion in 2020, and is estimated to reach \$6.80 billion by 2028, witnessing a CAGR of 20.9% from 2021 to 2028

PORTLAND, OREGON, UNITED STATES, October 7, 2022 /EINPresswire.com/ -- As per research conducted by Allied Market Research, the global Liquid Biopsy Market garnered \$1.20 billion in 2020, and is estimated to reach \$6.80 billion by 2028, witnessing a CAGR of 20.9% from 2021 to 2028. The report offers an extensive analysis of



changing market trends, top segments, major investment pockets, regional scenarios, value chain, and competitive landscape.

Liquid Biopsy Market by Product & Service (Kits & Reagents, Platforms & Instruments, and Services), Circulating Biomarker (Circulating Tumor Cells, Extracellular Vesicles, Circulating Tumor DNA [ctDNA], and Other Biomarkers), Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, and Other Cancers), and End User (Hospitals & Laboratories and Government & Academic Research Centers): Global Opportunity Analysis and Industry Forecast, 2021-2028

What is liquid biopsy?

Liquid biopsies are non-invasive blood tests that detect tumor DNA & RNA fragments and circulating tumor cells (CTCs), which are released into the blood from the primary tumors and metastatic sites

How Big is Liquid Biopsy Market?

Asia-Pacific has the most noteworthy development rate in the market which is developing this is credited because of Asia-Pacific have a huge patient pool with an ascent in discretionary

cashflow, expansion in government drives to modernize medical services framework, and ascend in medical services expenditureAn expansion in the quantity of persistent illnesses that lead to organ disappointments is supposed to help the interest for defrosted blood.

Download Free Sample Report Now: https://www.alliedmarketresearch.com/request-sample/1891

Covid-19 Scenario:

The market has suspended early diagnosis programs owing to the lockdown imposed by government bodies. In addition, there has been a decrease in screenings, visits, therapies, and surgeries related to cancer.

The pandemic has also affected the logistics and supplies of cancer diagnostic raw materials and components and other essential commodities required for the production of liquid biopsy.

Speak to our Analysts to Understand the Impact of COVID-19 on Your Business:

https://www.alliedmarketresearch.com/connect-to-analyst/1891

VALUE PROPOSITIONS RELATED TO THE REPORT:

Powered with Complimentary Analyst Hours and Expert Interviews with Each Report Comprehensive quantitative and qualitative insights at segment and sub-segment level Covid 19 impact trends and perspective

Granular insights at global/regional/country level

Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment

Blanket coverage on competitive landscape

Winning imperatives

Exhaustive coverage on 'Strategic Developments' registered by leading players of the market Based on end user, the hospitals and laboratories segment accounted for the largest market share in 2020, contributing to 94% of the global Liquid biopsy market, and is estimated to continue its leadership status during the forecast period. However, the government and

academic research center segment is projected to witness the largest CAGR of 21.9% from 2021 to 2028.

Based on region, North America contributed to the largest market share in 2019, holding more than two-fifths of the total share, and is expected to maintain its dominant share in terms of revenue by 2028. However, Asia-Pacific is estimated to portray the highest CAGR of 22.7% during the forecast period. Other provinces covered in the report include LAMEA and Europe.

Some of the Top Players in the Global Market Are:

Johnson & Johnson
Laboratory Corporation of America Holdings
MDxHealth SA
QIAGEN N.V.
Bio-Rad Laboratories, Inc
Biocept Inc.
Guardant Health Inc.
Illumina, Inc.
F. Hoffmann-La Roche Ltd. (FOUNDATION MEDICINE, INC.)

Thermo Fisher Scientific Inc.

Inquire More About the Top Market Players Here:

https://www.alliedmarketresearch.com/purchase-enquiry/1891

Liquid Biopsy Market: By Region Outlook

North America (U.S., Canada) Europe (France, Germany, UK, Italy, Spain, Netherlands, Austria) Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea) Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa) Important Questions Being Answered by the Market Report

What is the liquid biopsy market size and growth?
What are the prominent and latest trends impacting the market?
Which regions will observe growth on new occasions?
Which players are adopting a functioning and planned framework to obtain customer loyalty?

Request Customization: https://www.alliedmarketresearch.com/request-for-customization/1891

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at \$699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Request for 14 days free trial: https://www.alliedmarketresearch.com/avenue/trial/starter

"We have also published few syndicated market studies in the similar area that might be of your interest.

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Sign up and

David Correa
Allied Analytics LLP
800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/594769818

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.